Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay.

Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay.
复制标题

DOI:
10.1016/j.virol.2009.06.013
复制
发表时间:
2009-09-01
期刊:
影响因子:
3.7
通讯作者:
Cohen, Jeffrey I.
Cohen, Jeffrey I.
中科院分区:
医学3区
文献类型:
--
作者:
Sashihara, Junji;Burbelo, Peter D.;Savoldo, Barbara;Pierson, Theodore C.;Cohen, Jeffrey I.

文献摘要

参考文献

被引文献

相似文献

EB病毒(EBV)中和抗体的测量对于评价候选疫苗非常重要。目前的中和试验是基于抗体对B细胞的EBV转化的抑制,需要6周进行。我们开发了一种快速、定量的流式细胞术检测方法,并表明通过新检测方法测量的中和抗体滴度与标准转化检测方法中的抗体滴度密切相关。已经显示针对EBV gp 350和gp 42的抗体阻断EBV对B细胞的感染。使用新的检测方法来量化针对这些糖蛋白的抗体,我们首次表明人血浆中含有高滴度的针对gp 42的抗体;这些滴度与EB病毒感染性或转化的中和相关。此外,我们表明,抗体滴度EBV gp 350与中和更强烈的相关性比抗体滴度gp 42。这些测定在评估候选EBV疫苗的抗体应答中应该是有用的。
Measurement of neutralizing antibodies to Epstein-Barr virus (EBV) is important for evaluation of candidate vaccines. The current neutralization assay is based on antibody inhibition of EBV transformation of B cells and requires 6 weeks to perform. We developed a rapid, quantitative flow cytometry assay and show that neutralizing antibody titers measured by the new assay strongly correlate with antibody titers in the standard transformation-based assay. Antibodies to EBV gp350 and gp42 have been shown to block infection of B cells by EBV. Using new assays to quantify antibodies to these glycoproteins, we show for the first time that that human plasma contains high titers of antibody to gp42; these titers correlate with neutralization of EBV infectivity or transformation. Furthermore, we show that antibody titers to EBV gp350 correlate more strongly with neutralization than antibody titers to gp42. These assays should be useful in accessing antibody responses to candidate EBV vaccines.
DOI: 10.1128/jvi.54.3.665-674.1985
发表时间: 1985-01-01
影响因子: 5.4
作者:
BEISEL, C;TANNER, J;KIEFF, E
通讯作者: KIEFF, E
DOI: 10.1099/0022-1317-73-2-449
发表时间: 1992-02-01
影响因子: 3.8
作者:
FINERTY, S;TARLTON, J;MORGAN, AJ
通讯作者: MORGAN, AJ
DOI: 10.1038/318287a0
发表时间: 1985-01-01
期刊: NATURE
影响因子: 64.8
作者:
EPSTEIN, MA;MORGAN, AJ;KIRKWOOD, JK
通讯作者: KIRKWOOD, JK
DOI: 10.1128/jvi.80.3.1549-1562.2006
发表时间: 2006-02-01
影响因子: 5.4
作者:
Bilello, JP;Morgan, JS;Desrosiers, RC
通讯作者: Desrosiers, RC
DOI: 10.1016/0264-410x(94)90240-2
发表时间: 1994-10-01
期刊: VACCINE
影响因子: 5.5
作者:
FINERTY, S;MACKETT, M;MORGAN, AJ
通讯作者: MORGAN, AJ